JP2019512222A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019512222A5 JP2019512222A5 JP2018546577A JP2018546577A JP2019512222A5 JP 2019512222 A5 JP2019512222 A5 JP 2019512222A5 JP 2018546577 A JP2018546577 A JP 2018546577A JP 2018546577 A JP2018546577 A JP 2018546577A JP 2019512222 A5 JP2019512222 A5 JP 2019512222A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- terminal
- mhc
- amino acid
- multimeric
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 125
- 229920001184 polypeptide Polymers 0.000 claims 114
- 102000004196 processed proteins & peptides Human genes 0.000 claims 114
- 108700018351 Major Histocompatibility Complex Proteins 0.000 claims 25
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 claims 25
- 125000003275 alpha amino acid group Chemical group 0.000 claims 20
- 230000002519 immonomodulatory effect Effects 0.000 claims 18
- 102000002627 4-1BB Ligand Human genes 0.000 claims 16
- 108010082808 4-1BB Ligand Proteins 0.000 claims 16
- 210000004899 c-terminal region Anatomy 0.000 claims 14
- 238000000034 method Methods 0.000 claims 7
- 102000004169 proteins and genes Human genes 0.000 claims 7
- 108090000623 proteins and genes Proteins 0.000 claims 7
- 102000043131 MHC class II family Human genes 0.000 claims 4
- 108091054438 MHC class II family Proteins 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 210000001744 T-lymphocyte Anatomy 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 102000039446 nucleic acids Human genes 0.000 claims 4
- 150000007523 nucleic acids Chemical class 0.000 claims 4
- 102000043129 MHC class I family Human genes 0.000 claims 3
- 108091054437 MHC class I family Proteins 0.000 claims 3
- 230000000694 effects Effects 0.000 claims 3
- 239000013604 expression vector Substances 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 238000006467 substitution reaction Methods 0.000 claims 3
- 108060003951 Immunoglobulin Proteins 0.000 claims 2
- 108091008874 T cell receptors Proteins 0.000 claims 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 102000018358 immunoglobulin Human genes 0.000 claims 2
- 239000002773 nucleotide Substances 0.000 claims 2
- 125000003729 nucleotide group Chemical group 0.000 claims 2
- 244000052769 pathogen Species 0.000 claims 2
- 230000001717 pathogenic effect Effects 0.000 claims 2
- 230000001105 regulatory effect Effects 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 102000015736 beta 2-Microglobulin Human genes 0.000 claims 1
- 108010081355 beta 2-Microglobulin Proteins 0.000 claims 1
- 230000001747 exhibiting effect Effects 0.000 claims 1
- 239000000833 heterodimer Substances 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 210000004962 mammalian cell Anatomy 0.000 claims 1
- 108020004999 messenger RNA Proteins 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000013598 vector Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662303268P | 2016-03-03 | 2016-03-03 | |
| US62/303,268 | 2016-03-03 | ||
| PCT/US2017/020480 WO2017151940A2 (en) | 2016-03-03 | 2017-03-02 | T-cell modulatory multimeric polypeptides and methods of use thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019512222A JP2019512222A (ja) | 2019-05-16 |
| JP2019512222A5 true JP2019512222A5 (enExample) | 2020-04-09 |
| JP7372036B2 JP7372036B2 (ja) | 2023-10-31 |
Family
ID=59743280
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018546577A Active JP7372036B2 (ja) | 2016-03-03 | 2017-03-02 | Ｔ細胞調節多量体ポリペプチド及びその使用方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20190046648A1 (enExample) |
| EP (1) | EP3423078A4 (enExample) |
| JP (1) | JP7372036B2 (enExample) |
| KR (1) | KR20180132070A (enExample) |
| CN (1) | CN109414498A (enExample) |
| AU (1) | AU2017225787B2 (enExample) |
| CA (1) | CA3014466A1 (enExample) |
| IL (1) | IL261402A (enExample) |
| WO (1) | WO2017151940A2 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105121715B (zh) | 2012-12-11 | 2018-10-26 | 艾伯特叶史瓦大学爱因斯坦医学院 | 高通量受体:配体鉴定方法 |
| CA3022331A1 (en) | 2016-05-18 | 2017-11-23 | Albert Einstein College Of Medicine, Inc. | Variant pd-l1 polypeptides, t-cell modulatory multimeric polypeptides, and methods of use thereof |
| CN109475628A (zh) | 2016-05-18 | 2019-03-15 | 库尔生物制药有限公司 | T细胞调节性多聚体多肽及其使用方法 |
| AU2017379900B2 (en) | 2016-12-22 | 2024-12-05 | Cue Biopharma, Inc. | T-cell modulatory multimeric polypeptides and methods of use thereof |
| WO2018129474A1 (en) | 2017-01-09 | 2018-07-12 | Cue Biopharma, Inc. | T-cell modulatory multimeric polypeptides and methods of use thereof |
| EP3596118B1 (en) | 2017-03-15 | 2024-08-21 | Cue Biopharma, Inc. | Combination of multimeric fusion polypeptides and immune checkpoint inhibitor for treating hpv-associated cancer |
| CA3062591A1 (en) | 2017-05-08 | 2018-11-15 | Gritstone Oncology, Inc. | Alphavirus neoantigen vectors |
| WO2019036855A1 (en) | 2017-08-21 | 2019-02-28 | Adagene Inc. | Anti-cd137 molecules and use thereof |
| WO2019051127A1 (en) | 2017-09-07 | 2019-03-14 | Cue Biopharma, Inc. | MULTIMER MODULATOR POLYPEPTIDE OF LYMPHOCYTE T HAVING CONJUGATION SITES AND METHODS OF USE THEREOF |
| WO2019139896A1 (en) * | 2018-01-09 | 2019-07-18 | Cue Biopharma, Inc. | Multimeric t-cell modulatory polypeptides and methods of use thereof |
| WO2019148445A1 (en) | 2018-02-02 | 2019-08-08 | Adagene Inc. | Precision/context-dependent activatable antibodies, and methods of making and using the same |
| TW202000906A (zh) * | 2018-05-23 | 2020-01-01 | 美商葛利史東腫瘤科技公司 | 免疫檢查點抑制劑共表現載體 |
| EP3935079A4 (en) * | 2019-03-06 | 2023-03-22 | Cue Biopharma, Inc. | T LYMPHOCYTE MODULATOR ANTIGEN PRESENTING POLYPEPTIDES AND METHODS OF USE THEREOF |
| CN118852456A (zh) * | 2019-05-29 | 2024-10-29 | Cue生物制药股份有限公司 | 多聚体t细胞调节多肽及其使用方法 |
| MX2021014525A (es) | 2019-05-30 | 2022-03-17 | Gritstone Bio Inc | Adenovirus modificados. |
| CN114450305A (zh) * | 2019-06-05 | 2022-05-06 | 天演药业公司 | 抗cd137l抗体及其使用方法 |
| EP3986448A4 (en) * | 2019-06-19 | 2023-07-12 | Cue Biopharma, Inc. | MULTIMERIC T-CELL-MODULATING POLYPEPTIDES AND METHODS OF USE THEREOF |
| EP4030897A4 (en) * | 2019-09-20 | 2023-10-18 | Cue Biopharma, Inc. | T-cell modulatory polypeptides and methods of use thereof |
| EP4149534A4 (en) | 2020-05-12 | 2024-09-04 | Cue Biopharma, Inc. | MULTIMERIC POLYPEPTIDES MODULATING T CELLS AND METHODS OF USE THEREOF |
| CA3187258A1 (en) | 2020-08-06 | 2022-02-10 | Karin Jooss | Multiepitope vaccine cassettes |
| WO2022036495A1 (en) | 2020-08-17 | 2022-02-24 | Utc Therapeutics Inc. | Lymphocytes-antigen presenting cells co-stimulators and uses thereof |
| WO2022056014A1 (en) * | 2020-09-09 | 2022-03-17 | Cue Biopharma, Inc. | Mhc class ii t-cell modulatory multimeric polypeptides for treating type 1 diabetes mellitus (t1d) and methods of use thereof |
| MX2023008966A (es) * | 2021-02-07 | 2023-09-29 | Chia Tai Tianqing Pharmaceutical Group Co Ltd | Anticuerpo biespecifico. |
| WO2024088404A1 (en) * | 2022-10-28 | 2024-05-02 | Fbd Biologics Limited | Engineered 4-1bbl variants and methods of use thereof |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
| DE69233013T2 (de) | 1991-08-20 | 2004-03-04 | The Government Of The United States Of America As Represented By The Secretary Of National Institute Of Health, Office Of Technology Transfer | Adenovirus vermittelter gentransfer in den gastrointestinaltrakt |
| US5252479A (en) | 1991-11-08 | 1993-10-12 | Research Corporation Technologies, Inc. | Safe vector for gene therapy |
| FR2688514A1 (fr) | 1992-03-16 | 1993-09-17 | Centre Nat Rech Scient | Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant. |
| CA2592997A1 (en) | 1992-12-03 | 1994-06-09 | Genzyme Corporation | Pseudo-adenovirus vectors |
| JP3532566B2 (ja) | 1993-06-24 | 2004-05-31 | エル． グラハム，フランク | 遺伝子治療のためのアデノウイルスベクター |
| JP3875990B2 (ja) | 1993-10-25 | 2007-01-31 | カンジ，インコーポレイテッド | 組換えアデノウイルスベクターおよび使用方法 |
| US20050003431A1 (en) * | 1996-08-16 | 2005-01-06 | Wucherpfennig Kai W. | Monovalent, multivalent, and multimeric MHC binding domain fusion proteins and conjugates, and uses therefor |
| ATE321855T1 (de) * | 1997-01-14 | 2006-04-15 | Human Genome Sciences Inc | Tumor-nekrose-faktor rezeptor 5 |
| US7078387B1 (en) | 1998-12-28 | 2006-07-18 | Arch Development Corp. | Efficient and stable in vivo gene transfer to cardiomyocytes using recombinant adeno-associated virus vectors |
| WO2003006632A2 (en) * | 2001-07-12 | 2003-01-23 | Canvac | Methods and compisitions for activation human t cells in vitro |
| WO2003040307A2 (en) * | 2001-07-27 | 2003-05-15 | Human Genome Sciences, Inc. | Heteromultimeric tnf ligand family members |
| AU2002366433A1 (en) * | 2001-08-16 | 2003-09-09 | Human Genome Sciences, Inc. | Methods and compositions for treating metabolic bone diseases relating to human endokine alpha |
| US7138370B2 (en) * | 2001-10-11 | 2006-11-21 | Amgen Inc. | Specific binding agents of human angiopoietin-2 |
| US6911321B2 (en) * | 2001-12-19 | 2005-06-28 | Genentech, Inc. | Non-human primate Fc receptors and methods of use |
| US8895020B2 (en) * | 2002-04-19 | 2014-11-25 | Washington University | Single chain trimers and uses therefor |
| BRPI0707199A2 (pt) * | 2006-01-23 | 2011-04-26 | Novozymes As | polipeptìdeo, polinucleotìdeo isolado, construção de ácido nucleico, vetor de expressão recombinante, célula hospedeira recombinante, e, método para a produção de polipeptìdeo |
| EP2361930A3 (en) * | 2007-03-26 | 2011-10-26 | Dako Denmark A/S | Multimers of MHC-peptide complexes and uses thereof in Borrelia infectious diseases |
| CN102898504B (zh) * | 2012-10-23 | 2014-08-06 | 中国农业大学 | 抗氧化活性合成肽及其用途 |
| BR112016001114B1 (pt) * | 2013-07-19 | 2023-02-14 | Vib Vzw | Composição compreendendo uma proteína de fusão e uso da referida composição |
| SG10202006338UA (en) * | 2014-06-18 | 2020-08-28 | Albert Einstein College Medicine Inc | Syntac polypeptides and uses thereof |
| US11111284B2 (en) * | 2014-08-21 | 2021-09-07 | The General Hospital Corporation | Tumor necrosis factor superfamily and TNF-like ligand muteins and methods of preparing |
| CN109475628A (zh) * | 2016-05-18 | 2019-03-15 | 库尔生物制药有限公司 | T细胞调节性多聚体多肽及其使用方法 |
-
2017
- 2017-03-02 CA CA3014466A patent/CA3014466A1/en not_active Abandoned
- 2017-03-02 KR KR1020187028429A patent/KR20180132070A/ko not_active Ceased
- 2017-03-02 JP JP2018546577A patent/JP7372036B2/ja active Active
- 2017-03-02 US US16/077,303 patent/US20190046648A1/en not_active Abandoned
- 2017-03-02 AU AU2017225787A patent/AU2017225787B2/en not_active Ceased
- 2017-03-02 WO PCT/US2017/020480 patent/WO2017151940A2/en not_active Ceased
- 2017-03-02 EP EP17760833.8A patent/EP3423078A4/en not_active Withdrawn
- 2017-03-02 CN CN201780027393.7A patent/CN109414498A/zh active Pending
-
2018
- 2018-08-27 IL IL261402A patent/IL261402A/en unknown
-
2022
- 2022-10-03 US US17/958,904 patent/US20230330235A1/en not_active Abandoned